A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter Type 2, in Healthy Individuals at Steady State

By cbdweb On May 17, 2020

Cho N.H.
Shaw J.E.
Karuranga S.
et al.

IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045.

Diabetes Res Clin Pract. 2018; 138: 271-281

Bashier A.
Bin Hussain A.
Abdelgadir E.
Alawadi F.
Sabbour H.
Chilton R.

Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases.

Diabetol Metab Syndr. 2019; 11: 80

Yang W.
Lu J.
Weng J.
et al.

China national diabetes and metabolic disorders study group. Prevalence of diabetes among men and women in China.

N Engl J Med. 2010; 362: 1090-1101

Ojha A.
Ojha U.
Mohammed R.
Chandrashekar A.
Ojha H.

Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus.

Clin Pharmacol. 2019; 11: 57-65

Treatment and diagnosis of diabetes mellitus and its complication: advanced approaches.

Mini Rev Med Chem. 2015; 15: 1132-1133

Nathan D.M.
Buse J.B.
Davidson M.B.
et al.

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of diabetes.

Diabetes Care. 2009; 32: 193-203

CDA 2008 Clinical Practice Guidelines Steering Committee. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et al.

Diabetes Care. 2009; 32 (): e34

The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.

Annu Rev Med. 2015; 66: 255-270

Liu B.
Wang Y.
Zhang Y.
Yan B.

Mechanisms of protective effects of SGLT2 inhibitors in cardiovascular disease and renal dysfunction.

Curr Top Med Chem. 2019; 19: 1818-1849

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.

Drugs. 2015; 75: 33-59

Schumm-Draeger P.M.
Burgess L.
Korányi L.
Hruba V.
Hamer-Maansson J.E.
de Bruin T.W.

Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.

Diabetes Obes Metab. 2015; 17: 42-51

Bailey C.J.
Gross J.L.
Pieters A.
Bastien A.
List J.F.

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

Lancet. 2010; 375: 2223-2233

Nomura S.
Sakamaki S.
Hongu M.
et al.

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

J Med Chem. 2010; 53: 6355-6360

Sha S.
Devineni D.
Ghosh A.
et al.

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.

Diabetes Obes Metab. 2011; 13: 669-672

Donnan J.R.
Grandy C.A.
Chibrikov E.
et al.

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.

BMJ Open. 2019; 9e022577

Zou P.
Yu Y.
Zheng N.
et al.

Applications of human pharmacokinetic prediction in first-in-human dose estimation.

AAPS J. 2012; 14: 262-281

Zhang H.
Zhu X.
Li X.
et al.

Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus.

Diabetes Obes Metab. 2019; ()https://doi.org/10.1111/dom.13887

Komoroski B.
Vachharajani N.
Feng Y.
Li L.
Kornhauser D.
Pfister M.

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.

Clin Pharmacol Ther. 2009; 85: 513-519

LOWESS: a program for smoothing scatterplots by robust locally weighted regression.

The Am Statistician. 1981; 35: 54

Tobita H.
Sato S.
Miyake T.
Ishihara S.
Kinoshita Y.

Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study.

Curr Ther Res Clin Exp. 2017; 87: 13-19

Feng Y.
Zhang L.
Komoroski B.
Pfister M.

Population pharmacokinetic analysis of dapagliflozin in healthy subjects and patients with type 2 diabetes mellitus.

Clin Pharmacol Ther. 2010; 83: S93

Zhang H.
Zhu X.
Li Q.
et al.

Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus.

J Pharm Pharmacol. 2018; 70: 855-864

Zhang H.
Li Q.
Zhu X.
et al.

Association of variability and pharmacogenomics with bioequivalence of gefitinib in healthy male subjects.

Front Pharmacol. 2018; 9: 849

Rave K.
Nosek L.
Posner J.
Heise T.
Roggen K.
van Hoogdalem E.J.

Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes–results of a hyperglycaemic glucose clamp study.

Nephrol Dial Transpl. 2006; 21: 2166-2171

Terauchi Y.
Utsunomiya K.
Yasui A.
et al.

Safety and efficacy of empagliflozin as add-on therapy to GLP-1 receptor agonist (liraglutide) in Japanese patients with type 2 diabetes mellitus: a randomised, double-blind, parallel-group Phase 4 study.

Diabetes Ther. 2019; 10: 951-963

Kasichayanula S.
Liu X.
Pe Benito M.
et al.

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

Br J Clin Pharmacol. 2013; 76: 432-444

Kasichayanula S.
Chang M.
Hasegawa M.
et al.

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.

Diabetes Obes Metab. 2011; 13: 357-365

Devineni D.
Curtin C.R.
Polidori D.
et al.

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

J Clin Pharmacol. 2013; 53: 601-610

Garcia-Ropero A.
Badimon J.J.
Santos-Gallego C.G.

The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.

Expert Opin Drug Metab Toxicol. 2018; 14: 1287-1302

Toyama T.
Neuen B.L.
Jun M.
et al.

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis.

Diabetes Obes Metab. 2019; 21: 1237-1250

Samukawa Y.
Mutoh M.
Chen S.
Mizui N.

Mechanism-based pharmacokinetic-pharmacodynamic modeling of luseogliflozin, a sodium glucose Co-transporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.

Biol Pharm Bull. 2017; 40: 1207-1218

Cefalo C.M.A.
Cinti F.
Moffa S.
et al.

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.

Cardiovasc Diabetol. 2019; 18: 20

Chichger H.
Cleasby M.E.
Srai S.K.
Unwin R.J.
Debnam E.S.
Marks J.

Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.

Exp Physiol. 2016; 101: 731-742

Kasichayanula S.
Liu X.
Lacreta F.
Griffen S.C.
Boulton D.W.

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

Clin Pharmacokinet. 2014; 53: 17-27

Zhang M.
Zhang L.
Wu B.
Song H.
An Z.
Li S.

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.